Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Four companies set terms for NASDAQ IPOs: Repare, Forma, Progenity and Genetron

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s offering also earned it the largest

Read the full 411 word article

How to gain access

Continue reading with a
two-week free trial.